



OPAL BIOSCIENCES LIMITED

ABN 97 605 631 963

Level 4,

100 Albert Road,

South Melbourne, Victoria, 3205

Australia

Phone: +613 9692 7240

Web: www.opalbiosciences.com

Opal Information Memorandum

Melbourne, 19 July 2018: Opal Biosciences Limited today announced its Information Memorandum to raise up to \$1.5million through the issue of 6,000,000 shares at \$0.25 (25 cents) per share (with the possible issue of a further 4,000,000 shares at \$0.25 (25 cents) per Share to raise up to a further \$1.0million to satisfy over-subscriptions) and the issue of up to 10,000,000 options with an exercise price of \$0.25 (25 cents), expiring on 2 October 2019.

The Offer under the Information Memorandum opens on 19 July 2018, and will close on 2 October 2018 (or earlier if subscriptions are received up to the maximum oversubscription amount). These dates are indicative only and Opal reserves the rights to change the dates.

The proceeds from the capital raising will be used to fund further research and development activities, patent costs, general administrative and corporate costs, and other general working capital requirements.

The offer of shares and options pursuant to this Information Memorandum is only available to investors to whom an offer can be made without the need for a Disclosure Document to be provided under the Corporations Act 2001 (Cth). The Information Memorandum is not a prospectus or product disclosure document under the Corporations Act and has not been lodged with ASIC. The attention of potential investors is drawn to the *Important Notice* on page 2 of the Information Memorandum.

Application Forms can be obtained by contacting the office on (03) 9692 7240 or email reception@opalbiosciences.com or jphillips@opalbiosciences.com.

- ENDS -

About Opal Biosciences Limited

Opal Biosciences is an Australian biotechnology company and an innovative player in infectious disease treatment. The unmet need for new anti-infectives is due to increasing resistance to existing antibiotics, more widespread and common difficult-to-treat infections, and the paucity of upcoming new treatments. This need has spurred the EU and US to introduce significant financial incentives to encourage development of new anti-infectives.

Opal is currently seeking funding to support the next stage of development of its products including Opal-I, an injectable product.

For more information, please visit www.opalbiosciences.com.

Further information

Julie Phillips, Chief Executive Officer

Opal Biosciences Limited

Phone +61 3 9692 7240

Email jphillips@biodiem.com

Twitter @opalbiosciences